Drug Profile
Rucaparib
Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cancer Research UK
- Developer Alliance for Clinical Trials in Oncology; Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Clovis Oncology [CEASED]; Merck Sharp & Dohme; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; UNICANCER; University of Colorado at Denver; University of Oklahoma; University of Utah
- Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
- Phase II Breast cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Malignant-mesothelioma; Pancreatic cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
- Phase I/II Non-small cell lung cancer
- Suspended Malignant melanoma
- No development reported Gynaecological cancer
Most Recent Events
- 12 Oct 2023 The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopts positive opinion recommending approval of rucaparib as maintenance treatment for Ovarian cancer (Late-stage disease, Monotherapy), Peritoneal cancer (Late-stage disease, Monotherapy), and Fallopian tube cancer (Late-stage disease, Monotherapy) who are in response following completion of first-line platinum-based chemotherapy in European Union (PO)
- 30 Aug 2023 National Cancer Institute suspends a phase-III CASPAR trial for Prostrate cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (PO), as data from phase I trial of enzalutamide and rucaparib was being reviewed to determine the need for the PK substudy (NCT04455750)
- 26 May 2023 Chemical structure information added